Genetically predicted triglyceride lowering through the perturbation of LPL pathway activation targets ANGPTL4, APOC3, and LPL was associated with lower risk of CAD and T2D, and lower apoB. This evidence concerns the gene ANGPTL4 and coronary artery disorder.